116 patents
Page 5 of 6
Utility
Methods for Engineering Allogeneic and Immunosuppressive Resistant T Cell for Immunotherapy
9 Sep 20
Methods for developing engineered T-cells for immunotherapy that are both non-alloreactive and resistant to immunosuppressive drugs.
Roman GALETTO, Agnes GOUBLE, Stephanie GROSSE, Cecile MANNIOUI, Laurent POIROT, Andrew SCHARENBERG, Julianne SMITH
Filed: 16 May 20
Utility
Method for generating immune cells resistant to arginine and/or tryptophan depleted microenvironment
7 Sep 20
The present invention pertains to engineered immune cells, method for their preparation and their use as medicament, particularly for immunotherapy.
Laurent Poirot, Mathieu Simon
Filed: 9 Apr 15
Utility
Methods for Engineering T Cells for Immunotherapy by Using Rna-guided Cas Nuclease System
2 Sep 20
The present invention relates to methods of developing genetically engineered, preferably non-alloreactive T-cells for immunotherapy.
Philippe DUCHATEAU, André CHOULIKA, Laurent POIROT
Filed: 17 Feb 20
Utility
Trophoblast glycoprotein (5T4, TPBG) specific chimeric antigen receptors for cancer immunotherapy
31 Aug 20
The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a 5T4 monoclonal antibody, conferring specific immunity against 5T4 positive cells.
Cècile Schiffer-Mannioui
Filed: 2 Sep 15
Utility
Anti-GD3 specific chimeric antigen receptors for cancer immunotherapy
24 Aug 20
The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a GD3 monoclonal antibody, conferring specific immunity against GD3 positive cells.
Julianne Smith, Cècile Schiffer-Mannioui
Filed: 19 May 16
Utility
ROR1 (NTRKR1) specific chimeric antigen receptors for cancer immunotherapy
24 Aug 20
The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a ROR1 monoclonal antibody, conferring specific immunity against ROR1 positive cells.
Cècile Schiffer-Mannioui
Filed: 28 Jul 15
Utility
Tevi chimeric endonuclease and their preferential cleavage sites
10 Aug 20
The present invention relates to a method to cleave target nucleic acid sequence by the catalytic domain of a GIY-YIG homing endonucleases I-TevI.
George Silva, Marine Beurdeley
Filed: 21 Mar 17
Utility
Targeted Gene Integration of NK Inhibitors Genes for Improved Immune Cells Therapy
29 Jul 20
The invention pertains to the field of adaptive cell immunotherapy.
Brian BUSSER, Philippe DUCHATEAU, Alexandre JUILLERAT, Laurent POIROT, Julien VALTON
Filed: 8 Mar 18
Utility
Targeted Gene Insertion for Improved Immune Cells Therapy
15 Jul 20
The invention pertains to the field of adaptive cell immunotherapy.
Brian BUSSER, Philippe DUCHATEAU, Alexandre JUILLERAT, Laurent POIROT, Julien VALTON
Filed: 18 Oct 17
Utility
Cells for immunotherapy engineered for targeting CD38 antigen and for CD38 gene inactivation
13 Jul 20
Methods of developing genetically engineered immune cells for immunotherapy, which can be endowed with Chimeric Antigen Receptors targeting an antigen marker that is common to both the pathological cells and said CD38 immune by the fact that the genes encoding said markers are inactivated in said immune cells by a rare cutting endonuclease such as TALEN, Cas9 or argonaute.
Mathilde Dusseaux
Filed: 25 Jul 16
Utility
Methods of Antigen-dependent Chimeric Antigen Receptor (Car) Immune Cell Selection
8 Jul 20
The present disclosure provides in vitro and in vivo methods for selecting a candidate CAR polynucleotide to be expressed in immune cells for its preferential capability to make immune cells proliferate in an antigen-dependent manner.
Philippe DUCHATEAU, Anne-Sophie GAUTRON, Laurent POIROT
Filed: 25 Jul 18
Utility
Sequential Gene Editing In Primary Immune Cells
1 Jul 20
The invention pertains to the field of adaptive cell immunotherapy.
Jean-Pierre CABANIOLS, Jean-Charles EPINAT, Philippe DUCHATEAU
Filed: 29 Jun 17
Utility
Methods for Engineering T Cells for Immunotherapy by Using Rna-guided Cas Nuclease System
10 Jun 20
The present invention relates to methods of developing genetically engineered, preferably non-alloreactive T-cells for immunotherapy.
Philippe DUCHATEAU, André CHOULIKA, Laurent POIROT
Filed: 17 Feb 20
Utility
Potatoes with Reduced Cold-induced Sweetening
20 May 20
Materials and methods are provided for making plants (e.g., Solanum varieties) with decreased accumulation of reducing sugars and acrylamide in cold-stored potatoes, specifically, by making TALE-nuclease-induced mutations in genes encoding vacuolar invertase.
Luc Mathis, Daniel F. Voytas, Feng Zhang, Benjamin Clasen, William Haun, Thomas Stoddard
Filed: 24 Oct 19
Utility
Modifying Soybean Oil Composition Through Targeted Knockout of the FAD3A/B/C Genes
13 May 20
Materials and methods are provided for making soybean varieties that have altered oil composition as a result of mutations in the FAD3A, FAD3B, and FAD3C genes.
Luc Mathis, Zachary Demorest, Feng Zhang, William Haun
Filed: 17 Dec 19
Utility
Protease Based Switch Chimeric Antigen Receptors for Safer Cell Immunotherapy
6 May 20
The present invention relates to the field of cell immunotherapy and more particularly to a new generation of chimeric antigen receptors (CAR).
Philippe Duchateau, Alexandre Juillerat, Laurent Poirot
Filed: 10 May 18
Utility
Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease system
9 Mar 20
The present invention relates to methods of developing genetically engineered, preferably non-alloreactive T-cells for immunotherapy.
Philippe Duchateau, André Choulika, Laurent Poirot
Filed: 7 Feb 18
Utility
Alfalfa with Reduced Lignin Composition
12 Feb 20
Materials and methods for creating plants (e.g., alfalfa lines) with reduced lignin content and composition are provided herein, as are plants, plant parts, and plant cells generated by the methods provided herein.
Song Luo, Nicholas J. Baltes
Filed: 24 Apr 18
Utility
Modifying soybean oil composition through targeted knockout of the FAD3A/B/C genes
3 Feb 20
Materials and methods are provided for making soybean varieties that have altered oil composition as a result of mutations in the FAD3A, FAD3B, and FAD3C genes.
Luc Mathis, Zachary Demorest, Feng Zhang, William Haun
Filed: 1 Aug 18
Utility
ROR1 specific multi-chain chimeric antigen receptor
27 Jan 20
The present invention relates to a new generation of chimeric antigen receptors (CAR) referred to as multi-chain CARs, which are made specific to the antigen ROR1.
Cècile Schiffer-Mannioui
Filed: 28 Jul 15